Dietary Phosphate Restriction Normalizes Biochemical and Skeletal Abnormalities in a Murine Model of Tumoral Calcinosis

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2011 Oct 20

PMID 22009723

Citations 10

Authors

Shoji Ichikawa

Anthony M Austin

Amie K Gray

Matthew R Allen

Michael J Econs

Affiliations

Soon will be listed here.

Abstract

Mutations in the GALNT3 gene cause tumoral calcinosis characterized by ectopic calcifications due to persistent hyperphosphatemia. We recently developed Galnt3 knockout mice in a mixed background, which had hyperphosphatemia with increased bone mineral density (BMD) and infertility in males. To test the effect of dietary phosphate intake on their phenotype, Galnt3 knockout mice were generated in the C57BL/6J strain and fed various phosphate diets: 0.1% (low), 0.3% (low normal), 0.6% (normal), and 1.65% (high). Sera were analyzed for calcium, phosphorus, alkaline phosphatase, creatinine, blood urine nitrogen, 1,25-dihydroxyvitamin D, osteocalcin, tartrate-resistant acid phosphatase 5b, and fibroblast growth factor 23 (Fgf23). Femurs were evaluated by dual-energy x-ray absorptiometry, dynamic histomorphometry, and/or microcomputed tomography. Galnt3 knockout mice in C57BL/6J had the same biochemical phenotype observed in our previous study: hyperphosphatemia, inappropriately normal 1,25-dihydroxyvitamin D level, decreased alkaline phosphatase activity, and low intact Fgf23 concentration but high Fgf23 fragments. Skeletal analyses of their femurs revealed significantly high BMD with increased cortical bone area and trabecular bone volume. On all four phosphate diets, Galnt3 knockout mice had consistently higher phosphorus levels and lower alkaline phosphatase and intact Fgf23 concentrations than littermate controls. The low-phosphate diet normalized serum phosphorus, alkaline phosphatase, and areal BMD but failed to correct male infertility in Galnt3 knockout mice. The high-phosphate diet did not increase serum phosphorus concentration in either mutant or control mice due to a compensatory increase in circulating intact Fgf23 levels. In conclusion, dietary phosphate restriction normalizes biochemical and skeletal phenotypes of Galnt3 knockout mice and, thus, can be an effective therapy for tumoral calcinosis.

Citing Articles

Causal inference of inflammatory proteins in infertility: a Mendelian randomization study.

Chen P, Ni S, Ou-Yang L Front Endocrinol (Lausanne). 2025; 16:1448530.

PMID: 40070583 PMC: 11893426. DOI: 10.3389/fendo.2025.1448530.

Restriction of Dietary Phosphate Ameliorates Skeletal Abnormalities in a Mouse Model for Craniometaphyseal Dysplasia.

Fujii Y, Kozak E, Dutra E, Varadi A, Reichenberger E, Chen I J Bone Miner Res. 2021; 35(10):2070-2081.

PMID: 33463757 PMC: 9164311. DOI: 10.1002/jbmr.4110.

Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.

Boyce A, Lee A, Roszko K, Gafni R Front Endocrinol (Lausanne). 2020; 11:293.

PMID: 32457699 PMC: 7225339. DOI: 10.3389/fendo.2020.00293.

Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.

Courbon G, Martinez-Calle M, David V Curr Opin Nephrol Hypertens. 2020; 29(4):359-366.

PMID: 32452919 PMC: 7769207. DOI: 10.1097/MNH.0000000000000614.

Acute tumoral calcinosis due to severe hyperphosphatemia in a maintenance hemodialysis patient.

Nishime K, Takahashi H CEN Case Rep. 2017; 5(2):203-208.

PMID: 28508978 PMC: 5413758. DOI: 10.1007/s13730-016-0225-2.

References

Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D . Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med (Berl). 2004; 83(1):33-8. DOI: 10.1007/s00109-004-0610-8. View

Ohnishi M, Razzaque M . Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010; 24(9):3562-71. PMC: 2923352. DOI: 10.1096/fj.09-152488. View

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K . Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143(8):3179-82. DOI: 10.1210/endo.143.8.8795. View

Ichikawa S, Sorenson A, Austin A, Mackenzie D, Fritz T, Moh A . Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology. 2009; 150(6):2543-50. PMC: 2689800. DOI: 10.1210/en.2008-0877. View

Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse H . Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145(7):3087-94. DOI: 10.1210/en.2003-1768. View

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T . Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-60. DOI: 10.1210/jc.2002-021105. View

MCPHAUL Jr J, ENGEL F . Heterotopic calcification, hyperphosphatemia and angioid streaks of the retina. Am J Med. 1961; 31:488-92. DOI: 10.1016/0002-9343(61)90131-0. View

Garringer H, Mortazavi S, Esteghamat F, Malekpour M, Boztepe H, Tanakol R . Two novel GALNT3 mutations in familial tumoral calcinosis. Am J Med Genet A. 2007; 143A(20):2390-6. DOI: 10.1002/ajmg.a.31947. View

Ichikawa S, Imel E, Sorenson A, Severe R, Knudson P, Harris G . Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab. 2006; 91(11):4472-5. DOI: 10.1210/jc.2006-1247. View

10.

Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I . Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res. 2006; 22(2):235-42. DOI: 10.1359/jbmr.061105. View

11.

Narchi H . Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics. 1997; 99(5):745-8. DOI: 10.1542/peds.99.5.745. View

12.

Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N . A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab. 2005; 90(10):5523-7. DOI: 10.1210/jc.2005-0301. View

13.

Topaz O, Shurman D, Bergman R, Indelman M, Ratajczak P, Mizrachi M . Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004; 36(6):579-81. DOI: 10.1038/ng1358. View

14.

Carmichael K, Bynum J, Evans E . Familial tumoral calcinosis: a forty-year follow-up on one family. J Bone Joint Surg Am. 2009; 91(3):664-71. DOI: 10.2106/JBJS.G.01512. View

15.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561-8. PMC: 338262. DOI: 10.1172/JCI19081. View

16.

Joseph L, Hing S, Presneau N, ODonnell P, Diss T, Idowu B . Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. Skeletal Radiol. 2009; 39(1):63-8. DOI: 10.1007/s00256-009-0808-5. View

17.

Yamashita T, Nabeshima Y, Noda M . High-resolution micro-computed tomography analyses of the abnormal trabecular bone structures in klotho gene mutant mice. J Endocrinol. 2000; 164(2):239-45. DOI: 10.1677/joe.0.1640239. View

18.

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T . Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005; 289(5):F1088-95. DOI: 10.1152/ajprenal.00474.2004. View

19.

Ghanchi F, Ramsay A, Coupland S, Barr D, Lee W . Ocular tumoral calcinosis. A clinicopathologic study. Arch Ophthalmol. 1996; 114(3):341-5. DOI: 10.1001/archopht.1996.01100130337022. View

20.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt K . Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281(10):6120-3. PMC: 2637204. DOI: 10.1074/jbc.C500457200. View